Among the many central nervous system therapeutic areas associated with modulatory activity of the GABAA ion channel, GABAA α5-subtype negative allosteric modulators (NAMs) have been a focus of interest for the treatment of cognitive disorders. Join this webinar to learn how scientists identified a novel, orally active GABAA α5-selective NAM that improved hippocampal memory function without the anxiogenic-like or pro-convulsant effects associated with non-selective GABAA NAMs.
Through a case study of ONO-8590580, you’ll discover strategies to take a metabolically unstable hit compound through lead optimization, improving functional selectivity, absorption, distribution, metabolism, and excretion (ADME), pharmacokinetics (PK) and brain receptor occupancy along the way.
Mark Chambers, PhD
We are providing digital education options to keep you learning about topics you may be interested in. For more information, visit criver.com/digital-education.